2016-08-26T13:05:47-05:00 2015-12-31 721473527 HIENZ & MACALUSO LLC 110 VETERANS BLVD SUITE 170 METAIRIE LA 70005 990 2015-01-01 471643994 ANSWER ALS ANSW 8004902375 ONE GALLERIA BLVD NO 1100 METAIRIE LA 70001 PAUL VARISCO DIRECTOR 8004902375 2016-08-25 1 DAVID V ERNST P00751261 5048375434 2016-08-25 2015 2016-12-15 16:53:06Z X PAUL VARISCO ONE GALLERIA BLVD NO 1100 METAIRIE LA 70001 441120 0 X WWW.ANSWERALS.ORG X 2014 LA TO FIND SOLUTIONS FOR PEOPLE LIVING WITH ALS NOW AND FOR THE FUTURE BY UTILIZING KNOWLEDGE OF PATIENTS, LEADING RESEARCHERS AND TECHNOLOGY TO SEEK IMMEDIATE SOLUTIONS TO IMPROVE THE LIVES OF THOSE LIVING WITH ALS UNTIL A TREATMENT OR CURE IS FOUND; DISCOVER WHAT CAUSES ALS; DEVELOP MODELS TO UNDERSTAND ALS AND SCREEN FOR DRUG AND CELLULAR THERAPY; DISCOVER THERAPIES THAT COULD SUBSTANTIALLY SLOW OR HALT THE PROGRESS OF ALS AND ULTIMATELY CURE THE DISEASE; PROVIDE ALL GATHERED INFORMATION FREE FOR WORLDWIDE USE BY CLINICIANS, SCIENTISTS AND PHARMA TO RAPIDLY ADVANCE THERAPEUTICS. 3 3 0 12 0 0 440835 0 0 -1892 438943 0 0 0 0 48687 158679 158679 280264 280264 0 280264 X TO FIND SOLUTIONS FOR PEOPLE LIVING WITH ALS NOW AND FOR THE FUTURE BY UTILIZING KNOWLEDGE OF PATIENTS, LEADING RESEARCHERS AND TECHNOLOGY TO SEEK IMMEDIATE SOLUTIONS TO IMPROVE THE LIVES OF THOSE LIVING WITH ALS UNTIL A TREATMENT OR CURE IS FOUND; DISCOVER WHAT CAUSES ALS; DEVELOP MODELS TO UNDERSTAND ALS AND SCREEN FOR DRUG AND CELLULAR THERAPY; DISCOVER THERAPIES THAT COULD SUBSTANTIALLY SLOW OR HALT THE PROGRESS OF ALS AND ULTIMATELY CURE THE DISEASE; PROVIDE ALL GATHERED INFORMATION FREE FOR WORLDWIDE USE BY CLINICIANS, SCIENTISTS AND PHARMA TO RAPIDLY ADVANCE THERAPEUTICS. 0 0 99429 285 CREATING THE LARGEST AND MOST COMPREHENSIVE FOUNDATION OF ALS DATA EVER AMASSED, ENCOMPANSING CLINICAL, CHEMICAL, GENETIC, PROTEIN, HISTORICAL AND BIOLOGICAL DATA FROM AN ENORMOUS SAMPLING OF ALS PATIENTS IN THE UNITED STATES. IN COLLABORATION WITH MACHINE LEARNING AND BIG DATA TECHNOLOGY, THE DATA WILL BE MINED TO UNCOVER ALS CAUSES, SUBTYPES,PATHWAYS GONE AWRY AND DRUG TARGETS. THIS WILL ESTABLISH A LARGE AND CRITICAL FOUNDATION FOR NEW CLINICAL TRIALS, DEVELOP NEW WAYS TO CATEGORIZE PATIENTS TO IDENTIFY SPECIFIC DRUGGABLE PATHWAYS AND SUBTYPE BIOMARKERS AND DISEASE PATHOPHYSIOLOGY TO AID NOT ONLY IN EARLY DIAGNOSIS OF THE DISEASE, BUT ALSO TO MONITOR THE EFFICACY OF NEWLY DEVELOPED TREATMENTS. 99429 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 1 0 0 0 0 0 0 0 0 0 0 0 X 3 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 X THE ORGANIZATION 8004902375 ONE GALLERIA BLVD NO 1100 METAIRIE LA 70001 X PAUL VARISCO DIRECTOR 2.00 X X 0 0 0 TOM CAPELLA SECRETARY 2.00 X X 0 0 0 CLAIRE BURRETT BOARD MEMBER 1.00 X 0 0 0 0 0 0 0 0 0 0 0 67197 373638 440835 0 67197 2177 -2177 -2177 OTHER- MERCHANDISE SAL 624100 285 285 285 438943 285 0 -2177 X 975 975 119487 65807 7668 46012 2817 1394 1423 3488 2481 677 330 25201 24477 724 4731 3785 946 MISCELLANEOUS 1980 1485 297 198 158679 99429 10563 48687 199835 80429 0 280264 0 0 X 280264 0 280264 0 280264 280264 0 X 0 0 0 X 440835 440835 440835 440835 440835 440835 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED ANSWER ALS PATIENT PORTAL PROJECT 67197 67197 2177 67197 67197 2177 2177 -2177 FORM 990, PART VI, SECTION B, LINE 11 A COPY OF THE ORGANIZATION'S FORM 990 WILL BE PROVIDED TO THE ORGANIZATION'S GOVERNING BODY FOR REVIEW PRIOR TO IT BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS AND ENFORCES COMPLIANCE WITH THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION C, LINE 19 NO DOCUMENTS ARE PROVIDED TO THE GENERAL PUBLIC. FORM 990, PART IX, LINE 11G CONSULTING FEES: PROGRAM SERVICE EXPENSES 65807. MANAGEMENT AND GENERAL EXPENSES 7668. FUNDRAISING EXPENSES 46012. TOTAL EXPENSES 119487. GLEASON INITIATIVE FOUNDATION PO BOX 24493 NEW ORLEANS LA 70124 453689316 SEE PART VII FOR DESCRIPTION LA 501(C)(3) LINE 7 N/A 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 GLEASON INITIATIVE FOUNDATION C 353000 CASH SCHEDULE R, PAGE 1, PART II, COLUMN B PRIMARY ACTIVITY TO HELP PROVIDE INDIVIDUALS WITH MUSCULAR DISEASES OR INJURIES WITH LEADING EDGE TECHNOLOGY, EQUIPMENT AND SERVICES AND TO RAISE PUBLIC AWARENESS TOWARD AMYOTROPHIC LATERAL SCLEROSIS ALS BY PROVIDING & DOCUMENTING LIFE ADVENTURES FOR INDIVIDUALS WITH MUSCULAR DISEASES OR INJURIES